User: Guest  Login
Title:

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.

Document type:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Author(s):
Tedesco-Silva, H; Vítko, S; Pascual, J; Eris, J; Magee, JC; Whelchel, J; Civati, G; Campbell, S; Alves-Filho, G; Bourbigot, B; Garcia, VD; Leone, J; Esmeraldo, R; Rigotti, P; Cambi, V; Haas, T
Abstract:
The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full-dose cyclosporine (CsA) (Neoral). Two multicenter randomized controlled studies were performed to compare 12-month efficacy and safety of everolimus 1.5 and 3.0 mg/day with reduced-dose CsA. Study 1 enrolled 237 de novo renal allograft recipients, randomizing 222 nonblack patients to either everolimus 1.5 or 3.0 mg/day, with the Neoral) dose guided by C(2) (monitoring of CsA concentration 2 h after dosi...     »
Journal title abbreviation:
Transpl Int
Year:
2007
Journal volume:
20
Journal issue:
1
Pages contribution:
27-36
Language:
eng
Fulltext / DOI:
doi:10.1111/j.1432-2277.2006.00414.x
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/17181650
Print-ISSN:
0934-0874
TUM Institution:
Fachgebiet Nephrologie (Prof. Heemann)
 BibTeX